It implies that although combined therapy using these inhibitors along with tamoxifen has shown promising results in vitro and in vivo models, the following concerns need to be fully addressed before implementation of re-expression of ER therapy in clinics: (1) do all tumour cells respond to anti-oestrogens? The gene discussed is ESR1; the disease is neoplasm.